Hengrui Medicine: Injection SHR-A2102 Included in List of Breakthrough Therapies

Hengrui Pharmaceuticals announced that its subsidiary, Shanghai Hengrui Pharmaceuticals Co., Ltd., has had its injectable drug SHR-A2102 included in the list of breakthrough therapeutic products by the National Medical Products Administration Drug Evaluation Center. This drug is a therapeutic biological product, classified as Class 1 for registration, with the proposed indication for the treatment of recurrent or metastatic cervical cancer that has failed platinum-based chemotherapy and PD-1 inhibitor treatment.